Immunoscape scores $11M in international financing led by ANZU companions and UTEC

Immunoscape scores $11M in global financing led by ANZU partners and UTEC

Singapore-based biotech firm Immunoscape introduced that it has raised $11 million in a worldwide fairness financing spherical led by US-based enterprise agency Anzu Companions and joined by College of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.

The corporate, which was based in 2017, stated that its immune profiling platform, which offers deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 associated packages on three continents. It additionally has established collaborations with a number of vaccine growth firms, together with the San Diego-based Arcturus which is working scientific trials in Singapore.

ImmunoScape’s expertise was based mostly on work begun at Stanford College, and continued at A*STAR of Singapore (a statutory board below the Ministry of Commerce and Business). The corporate has acquired help from A*STAR and its commercialization arm A*ccelerate, in addition to Enterprise Singapore.

HIMSS20 Digital

Study on-demand, earn credit score, discover merchandise and options. Get Began >>

ON THE RECORD

“There may be an pressing want to know how the T-cell immune response contributes to COVID-19 immunity and may be leveraged for vaccine design,” stated ImmunoScape co-founder and Chief Working Officer Dr. Alessandra Nardin. 

“In international collaborations with Massachusetts Common Hospital, College of Parma (Italy), and Duke-NUS, we’re evaluating COVID-19 sufferers and recovered people. We’re constructing a big knowledge set on human T-cell response to COVID-19, in an effort to develop new therapies and higher vaccines with our companions.”

“As a Singapore-based agency supported by the Company for Science Expertise and Analysis (A*STAR), our workforce has deep expertise assessing T-cell immune response to dengue, hepatitis B, and different viruses. It was clear that we should present deep help to COVID-19 vaccine growth on this international disaster,” stated ImmunoScape co-founder and CEO Choon Peng Ng, previously a senior govt at A*STAR. 



Supply hyperlink

Be the first to comment

Leave a Reply